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The Arg-Gly-Asp (RGD) sequence is the most common motif
contained in a variety of matrix proteins, where it serves as the
recognition Site for diverse integrin receptors [1—3]. Matrix pro-
teins containing this particular or a related sequence include
fibronectin, vitronectin, laminin, thrombospondin, tenascin, von
Willebrand factor, osteopontin, Zn-a2-glycoprotein, and bone
sialoprotein 1 [4—9]. Integriri receptors that recognize this se-
quence include the entire a,, family, a5131, a3131, and aJ!bP3
integrins [10—121, as well as other receptors under specific condi-
tions, such as a2131 [121 and a4131 [13]. Synthetic RGD peptides
have been extensively exploited in in vitro studies of cell-matrix
and cell-cell interactions [14—16].
There is fledgling evidence that synthetic RGD peptides have
therapeutic potential in diverse pathological Situations. Explora-
tion of their potential in preventing the metastatic spread of B16
melonoma cell line [17, 181 revealed that RGD peptides signifi-
cantly reduce the formation of lung colonies in mice injected with
these cells. RGD peptides, as well as their natural analogs,
disintegrins, have been extensively studied as potential antithrom-
botic agents inhibiting platelet aggregation [19—23]. There is
on-going research on the therapeutic role of RGD peptides in
bone remodeling for management of osteoporosis [24].
Recent findings from several laboratories implicate integrins in
the pathophysiology of acute renal failure [25—29]. These obser-
vations provide a rationale for use of RGD peptides in the
management of this syndrome, and comprise the major subject of
this presentation.
Experimental evidence and pathophysiologic consequences of
redistribution of integrins in the kidney
Loss of polarity in integrin expression: In vitro evidence
Studies of intravitally-stained or fixed BSC-1 cells subjected to
oxidant stress yielded an intriguing observation on the loss of the
normal highly polarized distribution of several integrin receptors
[27]. Using confocal microscopy, we observed that cells growing as
a monolayer exhibited focal adhesions and integrins predomi-
nantly at the basolateral membranes (Fig. 1). Following oxidative
stress [27] or chemical hypoxia (Lieberthal, personal communica-
tion), this normal pattern underwent a rapid transformation from
a highly polarized to an ostensibly random distribution between
the apical and basolateral membranes.
Stress-induced loss of epithelial cell polarity is a well-recog-
nized biological phenomenon. The best studied precedent in
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epithelial cells is related to the hypoxia-induced loss of the polar
distribution of Na/K ATPase [30]. Other membrane proteins can
undergo repolarization or depolarization in response to stress.
The phenomenon of redistribution of the normally polarized
integrins is known to occur in keratinocytes and corneal epithelial
cells undergoing maturation and wound healing, respectively [31,
32], or during malignant transformation of epithelial cells [33—35].
The mechanisms governing this stress response are by and large
unknown.
The functional consequences of the loss of polarized distribu-
tion of integrins in renal tubular epithelial cells are twofold. First,
cell detachment from the matrix is a well-established consequence
of the dysfunction of several integrins. There is emerging evidence
that disruption of epithelial cell-matrix interactions leading to the
detachment of these anchorage-dependent cells induces apoptotic
cell death or anoikis (Greek term for homelessness) (Fig. 2A)
[36—38]. Second, the redistribution of integrins from the basal to
the apical cell membrane may predispose in situ cells to homo-
and heterophilic interactions with binding Sites on the dislodged
cells or with matrix fragments.
Loss of polarity in integrin expression: In vivo evidence
Integrins are abundantly expressed in the kidney. Immunohis-
tochemical localization of different subunits along the mammalian
nephron has revealed that proximal tubules express subunits a6,
a1 and, marginally, a3; distal tubules express subunits a1, a2, a3
and a6, and the /3 subunits are present along the entire tubule
[39—41].
Recent immunohistochemical studies (V. Romanov et al, in
press) of ischemic kidneys showed the most conspicuous staining
with antibodies to the /3 (labeling of the apical aspect of proximal
and distal tubules, as well as desquamated cells obstructing
tubular lumen) and to the a (glomeruli, tubular epithelia, intima
of blood vessels stained faintly, while the obstructing cellular
conglomerates showed intense staining) subunits (Fig. 2B). Ap-
plication of antibodies against the a3 subunit showed no staining
in control and a faint staining, which had the same topography as
the 13 subunit, of ischemic kidneys. These observations are
consistent with the proposed role of integrins in triggering the
cascade of events leading to cellular detachment and aggregation
of detached cells, as schematically depicted in Figure 3. In
addition, the schema predicts the possible inhibitory effect of
RGD peptides on homophilic and/or heterophilic interaction
between dislodged cells, as well as the adhesion of dislodged
epithelial cells to matrix proteins.
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Fig. 2. Immunohistochemical staining of ischemic kidneys. A. Dislodged
apoptotic epithelial cells within the tubular lumen, as revealed by peroxy-
dase Apoptag kit (Oncor, MD, USA). B, C. Mapping of RGD binding
Sites in control and ischemic kidney, respectively. D. Staining of dislodged
tubular epithelial cells with antibodies to the 1 integrin subunit.
Therapeutic effect of RGD peptides in ischemic acute renal
failure in the rat
Acute experiments
The role of integrins in ARF has also been confirmed in in vivo
experiments in rats with ischemic ARF by monitoring the proxi-
mal tubular pressure [28]. Dr. G.F. DiBona and one of us have
consistently observed the elevation of proximal tubular pressure,
as an index of tubular obstruction, in rats after the release of renal
artery occlusion. When a linear RGD peptide was injected into
the renal artery upon reperfusion, the elevation of proximal
tubular pressure was curtailed, the effect which was not repro-
duced by an inactive RGE peptide or by a vehicle alone [28].
These data are consistent with our proposed model of tubular
obstruction in ARF, suggesting that this ligand, acting as a decoy,
prevents integrin-mediated cell-cell interactions within the tubu-
lar lumen.
Chronic experiments
The above-mentioned studies have suggested that RGD pep-
tides may prevent tubular obstruction in the ischemic model of
ARF [28, 42, 43]. Therefore, we next examined in vivo chronic
effects of RGD peptides in ischemic ARF in rats [29]. Cyclic
RGDDFLG and RGDDFV-treated Sprague-Dawley rats sub-
jected to 45 minutes of renal ischemia followed by contralateral
nephrectomy showed a significantly lesser retention of creatinine
Fig. 1. Redistribution of integrins in BSC-1 cells
subjected to oxidant stress. BSC-1 cell
monolayers were intravitally stained with
antibodies to the a3 integrin subunit and
examined under a confocal microscope prior to
(A—D) and after (E—H) exposure to 1 mM
hydrogen peroxide. Planes A and E were
obtained from the apical cell surface, planes D
and H correspond to the basal cell surface.
Note the redistribution of fluorescence intensity
from the basal to the apical cell surface after
application of oxidant stress. Original
magnification )<400.
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(Cr), as well as an accelerated recovery of Cr on post-operative
day 1, compared to both control groups (animals treated with
either the inactive cyclic peptide or with the vehicle). In addition,
a significant difference in creatinine clearance (Cr) between
cyclic RGDDFLG or RGDDFV-treated and cyclic RDADFV-
treated groups was observed on post-operative day 3. These data
indicate that the recovery of renal function after ischemic injury
occurred faster in cyclic RGDDFV-treated (2 days) or
RGDDFLG-treated (3 days) groups, compared to animals treated
with either the inactive peptide or with the vehicle. When a single
injection of cyclic RGD peptides was performed two hours after
ischemia, it resulted in a degree of functional protection compa-
rable to that achieved with the injection immediately after the
release of the renal artery. The effectiveness of cyclic RGD
peptides was partly diminished when injected eight hours after
ischemia.
Histologic examination of kidneys obtained from rats treated
with the active peptide or with the vehicle revealed striking
differences in the degree of tubular obstruction. Forty-eight hours
after acute ischemia, peptide-treated kidneys showed no tubular
dilatation and a very mild tubular obstruction, compared with the
severely dilatated and obstructed tubules in the vehicle group.
Occasional necrotic and dividing tubular epithelial cells in situ
were observed with equal frequency in both groups. These data
suggest that cyclic RGD peptides do not affect significantly the
fate of tubular cells, such as lethal injury or mitogenesis. Rather,
they act by preventing tubular obstruction, a conclusion consistent
with the other findings. Thus, a single systemic administration of
cyclic peptides in vivo ameliorated acute ischemic renal failure,
probably through their inhibitory action on cell-cell conglomera-
tion in the tubular lumen.
Recently, several strategies to manipulate adhesion molecules
during the course of ischemic injury have been proposed. One
approach explores the therapeutic effects of anti-ICAM-1 and
anti-LFA-1 antibodies. It has been demonstrated that these
antibodies are effective in protection against acute ischemic
myocardial reperfusion [44, 45] and in renal ischemia [46, 47].
Most probably these effects are confined to the inhibition of
leukocyte rolling, arrest, and migration in the renal microvascular
bed. The approach described in the present work utilizing small,
Fig. 3. The proposed role of integrins in tubular
epithelial cell detachment and tubular obstruction.
filterable and less immunogenic peptides is directed toward
inhibition of tubular obstruction by the viable desquamated
epithelial cells [25, 26], thus aiming to improve urodynamics.
Presently, studies of the combined effect of anti-ICAM-1 antibod-
ies and RGD peptide are being conducted by Drs. Kelly and
Bonventre together with our laboratory. Preliminary results dem-
onstrate the additive effect of both therapeutics.
The above data present a strong circumstantial evidence of
RGD peptides-mediated prevention of tubular obstruction in
acute renal ischemia. The precise mapping of renal targets of
RGD therapy, however, is warranted to support this conclusion.
Possible modes of RGD peptide action
To investigate the topography of RGD binding sites within the
kidney, we next applied a "bait" strategy. A series of labeled RGD
peptides was synthesized: Tc-99m-labeled GRGDSPC, biotinyl-
ated cyclic RGDFV (Bt-cRGD), and rhodamine green-labeled
GRGDSP (RhoG-RGD). The rationale behind the applied strat-
egy is schematically presented in Figure 4. Assuming the above
hypothesis on the role of redistribution of integrins in the
pathophysiology of acute renal failure is correct, one would expect
that luminally-exposed integrins on tubular epithelium, either in
situ or dislodged, can be decorated with labeled ligands. The
results of experiments employing this "bait" strategy are summa-
rized below.
Clearance of RGD peptides
To evaluate the metabolism of RGD peptides, Tc-99m-
GRGDSPC was injected in a tail artery of normal Sprague-
Dawley rats and rats subjected to the 45 minutes of renal ischemia
followed by the contralateral nephrectomy (studies performed in
collaboration with Drs. Z. Oster and P. Som at the Brookhaven
National Laboratory). The clearance of radiolabeled RGD from
the blood in both groups of animals was rapid and indistinguish-
able between the control and ARF rats. In ARF group, renal
accumulation accounted for 3.53 1.24% (one kidney), while the
gut and liver accumulation accounted for 6.72 0.79% and
3.31 0.44%, respectively. The other organs (brain, lungs, heart,
spleen, and stomach) contained less than 1% of the injected dose
in both groups of animals. When the data were expressed per g
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Fig. 4. The rationale for a bait strategy
employing labeled RGD peptides to map binding
sites in ischemic kidneys.
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Fig. 5. The ratio 99m-Tc-RGD:lIIIn-DTPA in control and ischemic kid-
neys. (From [48], with permission of the American Society of Nephrology).
Representative ratio images are depicted above the corresponding bars.
wet tissue weight, the kidneys retained the largest portion of the
injected radioactivity at 10 minutes post-injection: 8.42 0.18%Ig
wet wt in control and 4.42 1.88%Ig wet wt in ARF rats [481.
When the results are expressed as the ratio of the activities
99m-Tc-GRGDSPC/111-In-DTPA, thus normalizing the amount
of the accumulated ROD peptide to the glomerular filtration rate,
post-ischemic kidneys retain a significantly higher fraction of the
filtered 99m-Tc-labeled RGD peptide compared to the normal
kidney (Fig. 5). Taking into account our previous findings of
surface expression of integrins on desquamation of tubular epi-
thelial cells, the above data suggest specific binding of the injected
99m-Tc-labeled RGD peptide to these exposed integrins. Based
on these results, it is quite plausible that the ratio 99m-Tc-RGD:
Ill -In-DTPA may serve as a diagnostic parameter for detection
of tubular obstruction in this and other pathological conditions.
Tissue distribution of RGD binding sites
A more precise mapping of ROD binding sites in ischemic rat
kidneys was performed using fluorescently-labeled peptides (Ro-
manov et al, in press). Two ROD peptides were synthesized: a
cyclic biotinylated (Bt)RGD peptide and a linear RGD peptide
(GRGDSP) labeled with rhodamine green (RhoG). In control,
Bt-RGD staining was undetectable, whereas RhoG-GRGDSP
staining faintly decorated the basolateral aspect of the proximal
tubular cells in a punctate fashion. In contrast, ischemic kidneys
showed binding to the basolateral and apical aspects of proximal
tubules, peritubular capillaries, and desquamated cells within
tubular lumen (Fig. 2, C, D). The expression of RGD binding sites
and f3 integrin subunits along the apical aspect of tubular
epithelia and on the surface of desquamated cells is in concert
with the hypothesis on the pathogenetic role of ROD-recognizing
integrins in tubular obstruction. Unexpectedly, expression of
RGD binding sites along the intimal surface of blood vessels in
ischemic kidneys was demonstrated, suggesting an additional
abnormality of integrin receptors in vascular endothelial cells. In
vitro application of cyclic ROD peptides inhibited HL-60 cell
adhesion to endothelial monolayers (V. Romanov et al, in press).
Collectively, these observations are consistent with the proposed
role of integrins in triggering the cascade of events leading to
cellular detachment, aggregation and tubular obstruction. Vascu-
lar endothelium may represent an additional target for RGD
peptides, as cartooned in Figure 6.
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Fig. 6. Schematic summaty of RGD binding sites
in the ischemic rat kidney. Specialized structures
along the nephron are magnified to denote
RGD binding sites on the intimal surface of
resistance arteries (a bright-field and
fluorescence view of the microdissected afferent
arteriole stained with rhodamine-labeled ROD
peptide), immunodetectable f3 subunits in the
proximal nephron on the surface of
desquamating or desquamated cells, and RGD
binding sites on the surface of epithelial cells
and cellular debris impacting the loop of Henle
and the distal nephron, as revealed with the
rhodamine-labeled RGD peptide.
—inhibition of
infiltration
Vasculature: —inhibiton of PMN transmigration
Fig. 7. Hypothetical schema of potential therapeutic effects of RGD peptides
in the kidney.
Summary and perspectives
In summary, the aberrant distribution and function of adhesion
molecules is gaining recognition as a pathophysiologically impor-
tant phenomenon in acute renal injury. The initial attempts to use
the knowledge on adhesion molecules to correct certain abnor-
malities of their distribution and function in disease were briefly
summarized above. These data justify further work, both experi-
mental and clinical trials, on elucidation of the therapeutic
potential of RGD peptides and their mimetics. In this vein, future
efforts will be focused not only on therapeutic role of RGD
peptides in acute renal injury, but should survey their potential in
a broad range of pathophysiological situations, where RGD motif
could be involved in vascular, glomerular, as well as tubular
abnormalities. These potential actions of RGD peptide are sum-
marized in Figure 7. As outlined, our future efforts will be
directed toward elucidation of anti-inflammatory and antiprolif-
erative properties of the peptide.
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